Prevention of venous thromboembolism in acute medical illness

Pharmacotherapy

Volumn 22, Issue 12 I, 2002, Pages 1564-1578

  Enders, Jason M ^a   Burke, John M ^a   Dobesh, Paul P ^a  

^a ST LOUIS COLLEGE OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN;

ACUTE HEART INFARCTION; ANTICOAGULATION; BLEEDING; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DOSIMETRY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GENERAL SURGERY; HEMATOMA; HIGH RISK PATIENT; HUMAN; INJECTION SITE; INTERMETHOD COMPARISON; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; ORTHOPEDIC SURGERY; PATHOPHYSIOLOGY; PROPHYLAXIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; THROMBOCYTOPENIA; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0036894230     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.17.1564.34124     Document Type: Review

References (90)

1. Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism: A statement for healthcare professionals from the Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. Circulation 1996;93:2212-45.
2. Anderson FA, Wheeler HB, Goldberg RJ, et al. A population- based perspective of the hospital frequency and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study. Arch Intern Med 1991;151:933-8.
3. Goldhaber SZ. Pulmonary embolism. N Engl J Med 1998;339:93-104.
4. Rubinstein I, Murray D, Hoffstein V. Fatal pulmonary embolism in hospitalized patients. Arch Intern Med 1998;148:1425-6.
5. Franzeck UK, Schalch I, Jager KA, et al. Prospective 12-year follow-up study of clinical and hemodynamic sequelae after deep vein thrombosis in low-risk patients (Zurich study). Circulation 1996;93:74-9.
6. Creager MA, Dzare VJ. Vascular diseases of the extremities. In: Braunwald E, Fauci AS, Kasper DL, et al, eds. Harrison's Principles of Internal Medicine, 15th Ed. New York: McGraw-Hill, 2001:1434-42.
7. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the frequency of deep vein thrombosis and pulmonary embolism. A 25-year population-based study. Arch Intern Med 1998;185:585-93.
8. Anderson FA, Wheeler HB, Goldberg RJ, et al. Physician practices in the prevention of VTE. Ann Intern Med 1991;115:591-5.
9. Arnold DM, Kahn SR, Shrier I. Missed opportunities for prevention of venous thromboembolism. An evaluation of the use of thromboprophylaxis guidelines. Chest 2001;120: 1964-71.
10. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001;119:132S-75.
11. Anderson FA, Wheeler HB, Goldberg RJ, Hosmer DW, Forcier A. The prevalence of risk factors for venous thromboembolism among hospital patients. Arch Intern Med 1992;152:1660-4.
12. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: Clinical outcomes in the international pulmonary embolism registry (ICOPER). Lancet 1999;353:1386-9.
13. Kniffin WD, Baron JA, Barrett J, Birkmeyer JD, Anderson FA. The epidemiology of diagnosed pulmonary embolism and deep vein thrombosis in the elderly. Arch Intern Med 1994;154:861-6.
14. Siddique RM, Siddique MI, Connors AF, Rimm AA. Thirty-day case-fatality rates for pulmonary embolism in the elderly. Arch Intern Med 1996;156:2343-7.
15. Carson JL, Kelley MA, Duff A, et al. The clinical course of pulmonary embolism. N Engl J Med 1992;326:1240-5.
16. Prandoni P, Lensing AWA, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7.
17. Virchow RLK. Thrombosis and Emboli (1846-1856). Science history publications. Canton, MA: Watson Publishing International, 1998.
18. Kirchhofer D, Nemerson Y. Initiation of blood coagulation: The tissue factor/factor VIIa complex. Curr Opin Biotechnol 1996;7:386-91.
19. Mann KG, van't Veer C, Cawthern K, Butenas S. The role of the tissue factor pathway in initiation of coagulation. Blood Coagul Fibrinolysis 1998;9:S3-7.
20. Brott, T, Stump D. Overview of hemostasis and thrombosis. Semin Neurol 1991;11:305-13.
21. Harker LA, Mann KG. Thrombosis and fibrinolysis. In: Verastraete M, Fuster V, Topol EJ, eds. Cardiovascular Thrombosis, 2nd Ed. Philadelphia: Lippincott-Raven, 1998:3-22.
22. Nurden AT. Polymorphisms of human platelet membrane glycoproteins: Structure and clinical significance. Thromb Haemost 1995;74:345-51.
23. Ginsberg MH, Du X, O'Toole TE, Loftus JC. Platelet integrins. Thromb Haemost 1995;74:352-9.
24. Phillips DR, Charo IF, Scarboroguh RM. GPIIb-IIIa: The responsive integrin. Cell 1991;65:359-62.
25. Plow EF, McEver RP, Coller BS, et al. Related binding mechanisms for fibrinogen, fibronectin, von Willebrand factor, and thrombospondin on thrombin-stimulated human platelets. Blood 1985;1985:724-7.
26. Badimon L, Badimon JJ, Fuster V. Pathogenesis of thrombosis. In: Verastraete M, Fuster V, Topol EJ, eds. Cardiovascular Thrombosis, 2nd Ed. Philadelphia: Lippincott-Raven, 1998:23-44.
27. Chandler AB. The anatomy of a thrombus. In: Sherry S, Brinkhous KM, Genton E, Stengle JM, eds. Thrombosis. Washington, DC: National Academy of Sciences, 1969:94-103.
28. Hirsh J, Crowther MA. Venous thromboembolism. In: Hoffman R, Benz EJ, Shattil SJ, et al, eds. Hematology: Basic Principles and Practice, 3rd Ed. New York: Churchill Livingstone, 2000:2074-89.
29. Colman RW, Marder VJ, Salzman EW, Hirsh J. Overview of hemostasis. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 3rd Ed. Philadelphia: JB Lippincott, 1994:1151-63.
30. Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989;264:4743-6.
31. Marlar RA, Kleiss AJ, Griffin J. Mechanism of action of human activated protein C, a thrombin-dependent enzyme. Blood 1982;59:1067-72.
32. Lindahl U, Kjellen L. Heparin or heparan sulfate - What is the difference? Thromb Haemost 1991;66:44-8.
33. Broze GJ Jr. Tissue factor pathway inhibitor. Thromb Haemost 1995;74:90-3.
34. Lijnen HR, Collen D. Interaction of plasminogen activators and inhibitors with plasminogen and fibrin. Semin Thromb Hemost 1982;8:2-10.
35. Aoki N, Harpel PC. Inhibitors of the fibrinolytic enzyme system. Semin Thromb Hemost 1984;10:24-41.
36. Kohler HP, Grant PJ. Mechanisms of disease: Plasminogen- activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000;342:1792-1801.
37. Sevitt S. The structure and growth of valve-pocket thrombi in femoral veins. J Clin Pathol 1974;27:517-28.
38. Salzman EW, Hirsh J. The epidemiology, pathogenesis, and natural history of venous thrombosis. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 3rd Ed. Philadelphia: JB Lippincott, 1994:1275-96.
39. Goldhaber SZ. Pulmonary embolism. In: Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine, 5th Ed. Philadelphia: WB Saunders, 1997:1582-1603.
40. Thromboembolic Risk Factors Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. BMJ 1992;305:567-74.
41. Handley AJ. Low dose heparin after myocardial infarction. Lancet 1972;2:623-4.
42. Warlow C, Beattie AG, Terry G, et al. A double-blind trial of low doses of subcutaneous heparin in the prevention of deep- vein thrombosis after myocardial infarction. Lancet 1973;2:934-6.
43. McCarthy ST, Turner JJ, Robertson D, et al. Low-dose heparin as prophylaxis against deep-vein thrombosis after acute stroke. Lancet 1977;2:800-1.
44. Dahan R, Houlbert D, Coulin C, et al. Prevention of deep vein thrombosis in elderly medical patients by a low molecular weight heparin: A randomized double-blind trial. Haemostasis 1986;16:159-64.
45. Turpie AGG, Levine MN, Hirsh J, et al. Double-blind randomized trial of ORG 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet 1987;1:523-6.
46. Kakkar AK, Williamson RCN. Prevention of VTE in cancer patients. Semin Thromb Hemost 1999;25:239-43.
47. Fisher B, Constantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 1998;90:1371-88.
48. Cade JF. High risk of the critically ill for venous thromboembolism. Crit Care Med 1982;10:448-50.
49. Belch JJ, Lowe GDO, Ward AG, et al. Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J 1981;26:115-17.
50. Samama MM, Cohen AT, Darmon J-Y, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999;341:793-800.
51. Ibarra-Perez C, Lau-Cortes E, Colmenero-Zubiate N, et al. Prevalence and prevention of deep venous thrombosis of the lower extremities in high-risk pulmonary patients. Angiology 1988;39:505-13.
52. Bergmann JF, Neuhart E. A multicenter randomized double- blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. Thromb Haemost 1996;76:529-34.
53. Hirsch DR, Igenito EP, Goldhaber SZ. Prevalence of deep venous thrombosis among patients in medical intensive care. JAMA 1995;274:335-7.
54. Lindblad B, Sternby NH, Bergqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years. BMJ 1991;302:709-11.
55. Kahn SR. The clinical diagnosis of deep venous thrombosis. Integrating frequency, risk factors, and signs and symptoms. Arch Intern Med 1998;158:2315-23.
56. Haines ST, Bussey HI. Diagnosis of deep vein thrombosis. Am J Health-Syst Pharm 1997;54:66-74.
57. Wheeler HB, Anderson FA. Diagnostic methods of deep vein thrombosis. Haemostasis 1995;25:6-26.
58. Davidson BL. What are the most reliable detection methods for deep vein thrombosis and pulmonary embolism to be used as endpoints in trials of venous thromboprophylaxis. Haemostasis 1998;28(suppl):113-19.
59. Wells PS, Lensing AWA, Davidson BL, Prins MH, Hirsh J. Accuracy of ultrasound for the diagnosis of deep venous thrombosis in asymptomatic patients after orthopedic surgery: A meta-analysis. Ann Intern Med 1995;122:47-53.
60. Davidson BL, Elliot CG, Lensing AWA. Low accuracy of color Doppler ultrasound in the detection of proximal leg vein thrombosis in asymptomatic high risk patients. Ann Intern Med 1992;117:735-8.
61. Rose SC, Zwiebel WJ, Murdock LE, et al. Insensitivity of color Doppler flow imaging for detection of acute calf deep venous thrombosis in asymptomatic postoperative patients. J Vasc Interv Radiol 1993;4:111-17.
62. Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: Are we detecting enough deep vein thrombosis? J R Soc Med 1989;82:203-5.
63. Hirsch J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin. Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119:64S-94.
64. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337:688-98.
65. Anderson LO, Barrowcliffe TW, Holmer E, et al. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration. Thromb Res 1976;9:575-83.
66. Glagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients: Results of meta-analysts. Ann Surg 1988;208:227-40.
67. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988;318:1162-73.
68. Kakkar VV, Corrigan TP, Fossard DP, et al. Prevention of fatal postoperative pulmonary embolism by low doses of heparin: An international multicentre trial. Lancet 1975;2:45-51.
69. Gallus AS, Hirsh J, Tuttle RJ, et al. Small subcutaneous doses of heparin in prevention of venous thrombosis. N Engl J Med 1973;288:545-51.
70. Halkin H, Goldberg J, Modan M, Modan B. Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis. Ann Intern Med 1982;96:561-5.
71. Gardlund B. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet 1996;347:1357-61.
72. Clarke-Pearson DL, Coleman RE, Synan IS, Hinshaw W, Creasman WT. Venous thromboembolism prophylaxis in gynecologic oncology: A prospective, controlled trial of lowdose heparin. Am J Obstet Gynecol 1983;145:606-13.
73. Clark-Pearson DL, DeLong E, Synan IS, et al. A controlled trial of two low-dose heparin regimens for the prevention of postoperative deep vein thrombosis. Obstet Gynecol 1990;75:684-9.
74. Kakkar VV, Corrigan T, Spindler J, et al. Efficacy of low doses of heparin in prevention of deep-vein thrombosis after major surgery: A double-blind, randomized trial. N Engl J Med 1972;2:101-6.
75. Dahan R, Houlbert D, Caulin C, et al. Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: A randomized double-blind trial. Haemostasis 1986;16:159-64.
76. Lechler E, Schramm W, Flosbach CW, et al. The venous thrombotic risk in non-surgical patients: Epidemiological data and efficacy/safety profile of a low-molecular weight heparin (enoxaparin). Haemostasis 1996;26(suppl 2):49-56.
77. Kleber FX, Witt C, Flosbach CW, et al. Study to compare the efficacy and safety of the LMWH enoxaparin and standard heparin in the prevention of thromboembolic events in medical patients with cardiopulmonary diseases [abstr]. Ann Hematol 1998;76(suppl I):A93.
78. Kleber FX, Flosbach CW, Koppenhagen K, et al. Comparison of the low molecular weight heparin in the prevention of venous thromboembolic events in patients with heart failure NYHA III/IV (PRINCE II study) [abstr]. Circulation 1999;100(suppl 1B):I-619.
79. Harenberg J, Schomaker U, Flosbach CW. Enoxaparin is superior to unfractionated heparin in the prevention of venous thromboembolic events in medical patients at increased thromboembolic risk [abstr]. Blood 1999;94(suppl 1):399a.
80. Hillborn M, Erila T, Sotaniemi K, et al. Comparison of the efficacy and safety of the low-molecular-weight heparin enoxaparin with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke [abstr]. Blood 1999;94(suppl 1):183a.
81. Poniewierski M, Barthels K, Kuhn M, Poliwoda H. Effectiveness of low molecular weight heparin (Fragmin) in the prevention of thromboembolism in internal medicine patients. A randomized double blind study. Med Klin 1998;83:241-5.
82. Fraisse F, Holzapfel L, Couland JM, et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. Association of non-university affiliated intensive care specialist physicians of France. Am J Respir Crit Care Med 2000;161(4 Pt 1):1109-14.
83. Bergmann JF, Caulin C. Heparin prophylaxis in bedridden patients. Lancet 1996;348:205-6.
84. Aquino JP, Gambier A, Ducros J. Prevention of thromboembolic accidents in elderly subjects with Fraxiparine. In: Bounameaux H, Samama MM, Ten Cate JW, eds. Fraxiaparine, 2nd International Symposium. Recent Pharmacological and Clinical Data. Stuttgart, New York: Schattauer 1990:51-4.
85. Harenberg J, Kallenabch B, Martin U, et al. Randomised controlled study of heparin and low molecular weight heparin for prevention of deep-vein thrombosis in medical patients. Thromb Res 1990;59:639-50.
86. Forette B, Wolmark Y. Calcium nadroparin in the prevention of thromboembolic disease in elderly subjects. Study of tolerance. Presse Med 1995;24:567-71.
87. Harenberg J, Roebruck P, Heene DL. Subcutaneous low- molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical patients. The heparin study in internal medicine (HESIM) group. Haemostasis 1996;26:127-39.
88. Manciet G, Vergnes C, Vaissie JJ, Boisseau MR. Etude de l'efficacite et de la tolerance de Fraxiparine administree au long cours chez le sujet age: etude randomisee en double insu (APTE). In: Bounameaux H, Samama MM, Ten Cate JW, eds. Fraxiaparine, 2nd International Symposium. Recent Pharmacological and Clinical Data. Stuttgart, New York: Schattauer, 1990:55-9.
89. Mismetti P, Laporte-Simitsidis S, Tracy B, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: A meta-analysis of randomized clinical trials. Thromb Haemost 2000;83:14-19.
90. Sifton DW, ed. 2002 Drug topics red book, 106th ed. Montvale, NJ: Thomson Medical Economics, 2002:367-8, 413.